argenx has more than a few significant changes brewing. The biopharma firm's founder and CEO is stepping down, making way for COO Karen Massey to move into the top position. Despite the leadership shakeup, sector analysts continue to maintain a strong faith in the firm's potential, with H.C. Wainwright and Jefferies continuing to rate argenx as a Buy, and price targets ranging from $950 at Jefferies to $1,264 at Wells Fargo. Argenx has experienced a setback, however, with the decision to discontinue its phase 3 UplighTED trials of efgartigimod SC in thyroid eye disease. Nevertheless, the firm remains undeterred by the disappointment, highlighting the growth of its Vyvgart drug and looking towards further expansions in the rare diseases market. A partnership with FUJIFILM Biotechnologies is also set to boost its manufacturing capabilities in the U.S., while an agreement with Unnatural Products worth $1.5B opens up new avenues in drug discovery.
argenx News Analytics from Tue, 01 Jul 2025 07:00:00 GMT to Sat, 10 Jan 2026 14:21:23 GMT -
Rating 5
- Innovation 7
- Information 8
- Rumor -6
